US Breast Cancer HCP Survey · n=300

Profile explorer

Layer the filters below to build any HCP profile. The page recomputes channels, formats, MSL, congress and KEE preferences for that slice - with an index vs the full sample.

Matching respondents
300/ 300 (100%)
Profile size
300
100% of sample
First-choice format
Discussion with peers
64% (i100)
Top MSL situation
After reviewing relev…
30% (i100)
Top-rated digital cadence
Meaningful change upd…
5.88 / 7

If/then playbook

Generated from the slice
  • 1
    Lead channels: prioritise Peer-reviewed journals and Discussions with peers.
  • 2
    Lead formats: open with Discussion with peers and Full-length peer-reviewed journal articles.
  • 3
    MSL focus: after reviewing relevant data independently, to clarify questions ?or uncertainties; secondary: to discuss upcoming pipeline developments.
  • 4
    Anchor news placements on Medscape and OncLive.
  • 5
    Social / professional emphasis: Doximity and Sermo.
  • 6
    Podcast partners: OncLive podcasts and Neil Love / Research To Practice.
  • 7
    Congress orchestration: pre - Expert perspectives on key topics expected to be discussed; during - Expert panel discussions; after - Expert perspectives on key topics expected to be discussed.

Top information sources

  • Peer-reviewed journals83%i100
  • Discussions with peers83%i100
  • Accredited Continuing Medical Education (CME) programs79%i100
  • Clinical guideline websites69%i100
  • Discussions with pharmaceutical company medical representatives (Medical Science Liaisons)58%i100
  • Medical news websites52%i100
  • In-person medical congresses51%i100
  • AI tools/generative AI platforms (e.g., ChatGPT or other large language models)47%i100

First-choice formats

  • Discussion with peers64%i100
  • Full-length peer-reviewed journal articles61%i100
  • Congress presentation or posters29%i100
  • Short articles29%i100
  • Live or on-demand expert discussions (e.g. Q&A, case discussions)29%i100
  • Audio content or podcasts (e.g., on-demand expert interviews, congress recaps)28%i100
  • Discussion with a Medical Science Liaison (MSL)25%i100
  • 2–3-minute video summaries16%i100

Medical news sites

  • Medscape35%i100
  • OncLive29%i100
  • ASCO Daily News26%i100
  • Cancer Network23%i100
  • Targeted Oncology23%i100
  • ReachMD6%i100
  • Healio Oncology5%i100

Social / professional platforms

  • Doximity22%i100
  • Sermo14%i100
  • X (Twitter)8%i100
  • LinkedIn7%i100

Podcasts

  • OncLive podcasts12%i100
  • Neil Love / Research To Practice11%i100
  • Oncology Brothers5%i100
  • ReachMD podcasts2%i100

When MSL adds most value

  • After reviewing relevant data independently, to clarify questions ?or uncertainties30%i100
  • To discuss upcoming pipeline developments22%i100
  • To discuss complex treatment sequencing or decision-making20%i100
  • As a follow-up after I requested medical info19%i100
  • As a first introduction to new clinical or trial data17%i100
  • To explore safety, tolerability, or real-world experience in more depth16%i100

Digital cadence acceptability (mean 1–7)

  • Meaningful change updated only – Receiving updates only when there is practice changing evidence or a meaningful change to guidelines or standard of care5.88 / 7
  • Around major congresses only – Receiving updates only around major scientific congresses (pre- and post-congress), with minimal communication outside those periods5.25 / 7
  • Ad hoc – Receiving occasional ad hoc updates only when a new data release is highly relevant5.25 / 7
  • Monthly roundup – Receiving one monthly update summarizing all data relevant to my specialty4.59 / 7
  • Quarterly summary – Receiving a quarterly summary of the most important updates relevant to my specialty4.49 / 7
  • I generally prefer not to receive digital updates and instead access information independently when needed3.09 / 7

Acceptability of digital approaches (mean 1–7)

Congress journey

Beforecongress
  • Expert perspectives on key topics expected to be discussed41%i100
  • Refreshers on existing data or current treatment approaches38%i100
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%i100
  • Study design overviews or key endpoints to watch32%i100
  • Summaries of key trials to watch out for31%i100
Duringcongress
  • Expert panel discussions43%i100
  • Clinical practice or case-based sessions32%i100
  • Guideline update sessions31%i100
  • Oral abstract sessions presenting late‑breaking or pivotal data25%i100
  • Peer discussions24%i100
  • Poster sessions and focused ?poster discussions14%i100
Aftercongress
  • Expert perspectives on key topics expected to be discussed41%i100
  • Refreshers on existing data or current treatment approaches38%i100
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%i100
  • Study design overviews or key endpoints to watch32%i100
  • Summaries of key trials to watch out for31%i100

Top KEEs in this slice

  • Hope Rugo17 mentions
  • Sara Tolaney7 mentions
  • Paolo Tarantino6 mentions
  • Ann Partridge3 mentions
  • Tiffany Traina3 mentions
  • Nancy Lin2 mentions